These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31353239)

  • 1. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study.
    Oh CK; Bang JB; Kim SJ; Huh KH; Kim SJ; Jeon JS; Han SY; Cho HR; Kwon YJ; Lee SH; Kim YS
    Asian J Surg; 2020 Jun; 43(6):660-667. PubMed ID: 31353239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients.
    Bäckman L; Persson CA
    Ann Transplant; 2014 Mar; 19():138-44. PubMed ID: 24637379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment satisfaction in renal transplant patients taking tacrolimus once daily.
    van Boekel GA; Kerkhofs CH; Hilbrands LB
    Clin Ther; 2013 Nov; 35(11):1821-9.e1. PubMed ID: 24135441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen.
    Eberlin M; Otto G; Krämer I
    Transplant Proc; 2013; 45(6):2314-20. PubMed ID: 23726723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence.
    Godinas L; Dobbels F; Hulst L; Verbeeck I; De Coninck I; Berrevoets P; Schaevers V; Yserbyt J; Dupont LJ; Verleden SE; Vanaudenaerde BM; Ceulemans LJ; Van Raemdonck DE; Neyrinck A; Verleden GM; Vos R
    J Heart Lung Transplant; 2021 Jun; 40(6):467-477. PubMed ID: 33840608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients.
    Guirado L; Cantarell C; Franco A; Huertas EG; Fructuoso AS; Fernández A; Gentil MA; Rodríguez A; Paul J; Torregrossa JV; Rodríguez A; Alonso A; Hernández D; Burgos D; Jiménez C; Jimeno L; Lauzurica R; Mazuecos A; Osuna A; Plumed JS; Ruiz JC; Zárraga S;
    Am J Transplant; 2011 Sep; 11(9):1965-71. PubMed ID: 21668633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients.
    Jun H; Kim MG; Jung CW
    Int J Clin Pharmacol Ther; 2016 Feb; 54(2):81-6. PubMed ID: 26709601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.
    Silva HT; Felipe CR; Garcia VD; Neto ED; Filho MA; Contieri FL; de Carvalho DD; Pestana JO
    Am J Transplant; 2013 Dec; 13(12):3155-63. PubMed ID: 24266969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.